How far will the Voyager® take us?
- PMID: 30767555
- PMCID: PMC6499013
- DOI: 10.2217/cns-2018-0019
How far will the Voyager® take us?
Keywords: PD-1 inhibitor; electromagnetic fields; glioblastoma; paclitaxel mimic.
Conflict of interest statement
The author is the Founder and Senior Medical Adviser for Orbus Therapeutics, DMC Chair for Bristol-Myers Squibb clinical trials and a member of SAB for Nativis, Inc.
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Comment on
-
An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US.CNS Oncol. 2019 Mar;8(1):CNS30. doi: 10.2217/cns-2018-0013. Epub 2018 Dec 14. CNS Oncol. 2019. PMID: 30547676 Free PMC article. Clinical Trial.
-
A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia.CNS Oncol. 2019 Mar;8(1):CNS31. doi: 10.2217/cns-2018-0017. Epub 2019 Feb 7. CNS Oncol. 2019. PMID: 30727742 Free PMC article. Clinical Trial.
References
-
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. - PubMed
-
- Cohen AL, Colman H. Glioma biology and molecular markers. Cancer Treat. Res. 2015;163:15–30. - PubMed
-
- Sulman EP, Ismaila N, Armstrong TS, et al. Radiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J. Clin. Oncol. 2017;35(3):361–369. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical